-
Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug
Wednesday, August 22, 2018 - 10:50am | 356Shares of Netherlands-based biotech argenx SE – ADR (NASDAQ: ARGX) were trading up Wednesday following an announcement concerning its immuno-oncology antibody AGRX-115. What Happened Argenx said AbbVie Inc (NYSE: ABBV) has opted to exercise its exclusive option to license and...